Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis;Miltefosina versus antimoniato de meglumina en el tratamiento de la leishmaniasis mucosa

Medicina (Argentina)

Volumn 74, Issue 5, 2014, Pages 371-377

  García Bustos, María F ^a   Barrio, Alejandra ^b   Parodi, Cecilia ^c   Beckar, Josefina ^d   Moreno, Sonia ^e   Basombrío, Miguel A ^a  

^a National Council of Scientific and Technical Researches   (Argentina)

^b UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^c Academia Nacional de Medicina ^*  (Argentina)

^d Hospital San Bernardo   (Argentina)

^e Hospital Señor del Milagro   (Argentina)

Author keywords

Leishmaniasis treatment; Miltefosine; Mucocutaneous leishmaniasis

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND; PHOSPHORYLCHOLINE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INJURY SEVERITY; LEISHMANIASIS; MUCOSAL LEISHMANIASIS; PHASE 2 CLINICAL TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; INJURY SCALE; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MIDDLE AGED; NASOPHARYNX; PARASITOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; HUMANS; INJURY SEVERITY SCORE; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; NASOPHARYNX; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE; YOUNG ADULT;

EID: 84926378336     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Salomón OD, Quintana MG, Mastrángelo AV, Fernández MS. Leishmaniasis and Climate Change–Case Study: Argentina. J Trop Med 2012; 2012: 601242.
2. Organización Panamericana de la Salud. Curso de autoaprendizaje de Leishmaniasis en las Américas: diagnóstico y tratamiento. En: http://cursos.campusvirtualsp.org/course/view.php?id=133&pageid=3230;consultadoel08/05/2014.
3. Salomón OD, Orellano PW, Quintana MG, et al. Transmisión de la leishmaniasis tegumentaria en la Argentina. Medicina (B Aires) 2006; 66:211-9.
4. Sosa Estani S, Segura EL, Salomón OD, et al. Tegumentary Leishmaniasis in Northern Argentina: distribution of infection and disease, in three municipalities of Salta, 1990-1992. Rev Soc Bras Med Trop 2000; 33: 573-82.
5. Barrio AB, García Bustos MF, Mora MC, et al. Identificación por PS–PCR de especies de Leishmania y su correlación con características clínicas, epidemiológicas y terapéuticas en Salta, Argentina. Revista Argentina de Salud Pública 2009; 1: 30-3.
6. Marco JD, Barroso PA, Calvopiña M, et al. Species assignation of Leishmania from human and canine American Tegumentary Leishmaniasis cases by multilocus enzyme electrophoresis in north Argentina. Am J Trop Med Hyg 2005; 72: 606-11.
7. Strazzulla A, Cocuzza S, Pinzone MR, et al. Mucosal Leishmaniasis: An Underestimated Presentation ofa Neglected Disease. Biomed Res Int 2013; 2013: 805108.
8. McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. Q J Med 2014; 107: 7-14.
9. World Health Organization. Control of the Leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva, 2010. En:http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf;consultadoel16/05/2014.
10. Vélez Bernal ID, Robledo Restrepo SM. Leishmaniasis. Fontilles, Rev Leprol 2010; 27: 367-96.
11. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travelers. Trans R Soc Trop Med Hyg 2006; 100: 264-9.
12. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection. J Infect Dis 2006; 193: 1375-83.
13. Serrano-Martín X, Payares G, De Lucca M, Martínez JC, Mendoza-León A, Benaim G. Amiodarone and Miltefosine Act Synergistically against Leishmania mexicana and Can Induce Parasitological Cure in a Murine Model of Cutaneous Leishmaniasis. Antimicrob Agents Chemother 2009; 53: 5108-13.
14. Sundar S, Jha TK, Thakur CP, et al. Oral Miltefosine for Indian Visceral Leishmaniasis. N Engl J Med 2002; 347: 1739-46.
15. Soto J, Toledo J, Valda L, et al. Treatment of mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44: 350-6.
16. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78: 210-1.
17. Soto J, Berman J. Treatment of New World Cutaneous Leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006; 100: 34-40.
18. The Cochrane Collaboration. Glosario de términos de la Colaboración Cochrane, 2005. En: http://www.cochrane.es/files/handbookcast/Glosario_Manual_Cochrane_425.pdf; consultado el 17/05/2014.
19. Barrio A, Mora MC, Ramos F, Moreno S, Samson R, Basombrío MA. Use of kDNA-based polymerase chain Reaction as a sensitive and differentially diagnostic method of American Tegumentary Leishmaniasis in disease-endemic areas of Northern Argentina. Am J Trop Med Hyg 2007; 77: 636-9.
20. Organización Panamericana de la Salud. Leishmaniasis en las Américas - Recomendaciones para el tratamiento. Washington, DC. 2013. En: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=22226&Itemid=; consultado el 18/05/2014.
21. Ministerio de Salud. Presidencia de la Nación. Dirección de Calidad de los Servicios de Salud. Programa Nacional de Garantía de la Calidad de la Atención Médica. Resolución 386/2004. Manual de Procedimientos para el Nivel Gerencial y Profesional sobre Leishmaniosis. En: http://www.msal.gov.ar/pngcam/resoluciones/msres386_2004.pdf; consultado el 19/05/2014.
22. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Bethesda, Md: U.S. Department of Health and Human Services, National Institutes of Health, 2010.En: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf; consultado el 20/05/2014.
23. Llanos-Cuentas A, Echevarría J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997; 25: 677-84.
24. Barral A, Pedral-Sampaio D, Grimaldi G, Jr., et al. Leishmaniasis in Bahia, Brazil: Evidence that Leishmania amazonensis Produces a Wide Spectrum of Clinical Disease. Am J Trop Med Hyg 1991; 44: 536-46.
25. Lucas CM, Franke ED, Cachay MI, et al. Geographic distribution and clinical description of Leishmaniasis cases in Perú. Am J Trop Med Hyg 1998; 59: 312-7.
26. Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007: 156: 1328-35.
27. Silveira FT, Lainson R, Corbett CEB. Clinical and immunopathological spectrum of American Cutaneous Leishmaniasis with special reference to the disease in Amazonia, Brazil – A review. Mem Inst Osw Cruz 2004; 99: 239-51.
28. Silveira FT, Blackwell JM, Ishikawa EA, et al. T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia. Parasite Immunol 1998; 20: 19-26